Company news
Duality Biotherapeutics, Inc. (HKEX:9606) news
Duality Biotherapeutics, Inc. news releases on 6ix. Latest, Sep 30, 2026: An announcement has just been published by the issuer in the Chinese section of this…
Press releases & updates
An announcement has just been published by the issuer in the Chinese section of this website, a corresponding version of which may or may not be published in this section
September 30, 2026
Next Day Disclosure Return
September 29, 2026
Next Day Disclosure Return
September 28, 2026
2026 INTERIM REPORT
September 28, 2026
DualityBio Announces China NMPA Acceptance of Biologics License Application Seeking Approval for Trastuzumab Pamirtecan for the Treatment of Unresectable or Metastatic HER2-Positive Adult Breast Cancer
April 9, 2026
DualityBio (9606.HK) Announces 2025 Annual Results
March 24, 2026
DualityBio's Next-Generation HER3 ADC DB-1310 Granted FDA Fast Track Designation
July 20, 2025
First Patient Dosed in Phase 1/2 Clinical Study of Novel EGFR/HER3 Bispecific Antibody-Drug Conjugate AVZO-1418/DB-1418
July 7, 2025
Preliminary Data from Two Clinical Trials with ADC Candidates were Presented Orally at the 2025 ASCO Annual Meeting
June 4, 2025
FDA Clearance of Investigational New Drug Application Received for Novel EGFR/HER3 Bispecific Antibody-Drug Conjugate AVZO-1418/DB-1418
May 22, 2025